Certis Oncology Solutions

Certis Oncology Solutions is a private, pre-revenue biotechnology company pioneering a data-driven approach to translational oncology. The company's platform integrates AI-driven predictive analytics with sophisticated, biologically complex cancer models, such as patient-derived organoids and xenografts, to generate highly actionable insights for drug developers. By offering these capabilities as a service and potentially as a platform, Certis targets the critical bottleneck in oncology R&D: the high failure rate of drugs that show promise in conventional models but fail in human trials. The company's value proposition lies in improving the predictive validity of preclinical data, thereby helping pharmaceutical and biotech partners select better drug candidates and design more effective clinical trials.

Integrated platform combining predictive artificial intelligence (AI) with advanced, patient-derived cancer models (e.g., patient-derived xenografts/organoids) to generate clinically translatable data for oncology drug development.

Certis competes in a fragmented market including large preclinical contract research organizations (CROs) offering standard models, specialized providers of patient-derived models, and a growing number of AI/ML-focused drug discovery companies. Its key differentiation is the tight integration of complex biological models with proprietary predictive analytics, aiming to offer an end-to-end translational insight service rather than just a data generation or software tool.